Sol-Gel Technologies Ltd (SLGL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sol-Gel Technologies Ltd (SLGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8024
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sol-Gel Technologies Ltd (Sol-Gel) is a clinical-stage dermatology company that identifies, develops and commercializes branded and generic topical dermatological drug products for the treatment of skin diseases. The company’s pipeline products include vered, twin and sirs-t drug candidates. Its twin drug candidate is a non-antibiotic topical cream developed for the treatment of acne vulgaris or acne. Sol-Gel’s vered drug candidate is a topical encapsulated benzoyl peroxide cream developed for the treatment of papulopustular rosacea. The company’s sirs-t drug candidate is topical encapsulated tretinoin cream developed for the potential treatment of acne. It also develops silica-based microencapsulation technology platform. Sol-Gel is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd (SLGL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sol-Gel Technologies Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Sol-Gel Technologies Enters into Agreement with Perrigo Israel Pharma 11
Sol-Gel Technologies Enters into Agreement with CMO 12
Sol-Gel Technologies Amended Development Agreement with Perrigo 13
Licensing Agreements 14
Douglas Pharma Enters into Licensing Agreement with Sol-Gel Technologies 14
Sol-Gel Technologies Enters Into Licensing Agreement With US-Based Pharma Company For Dermatologic Drug 15
Equity Offering 16
Sol-Gel Tech Raises USD86.3 Million in IPO of Shares 16
Acquisition 18
Mori Arkin Plans to Acquire Sol-Gel for USD10 Million 18
Sol-Gel Technologies Ltd – Key Competitors 19
Sol-Gel Technologies Ltd – Key Employees 20
Sol-Gel Technologies Ltd – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
May 15, 2018: Sol-Gel Technologies Announces First Quarter 2018 Financial Results 22
Mar 26, 2018: Sol-Gel Technologies Reports Fourth Quarter and Full Year 2017 Financial Results 23
Corporate Communications 25
Sep 13, 2018: Sol-Gel Technologies Names Jonathan B. Siegel to the Board of Directors 25
Clinical Trials 26
Feb 15, 2018: Sol-Gel presents Phase 2 Data on VERED at the 2018 American Academy of Dermatology Annual Meeting 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sol-Gel Technologies Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Sol-Gel Technologies Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sol-Gel Technologies Enters into Agreement with Perrigo Israel Pharma 11
Sol-Gel Technologies Enters into Agreement with CMO 12
Sol-Gel Technologies Amended Development Agreement with Perrigo 13
Douglas Pharma Enters into Licensing Agreement with Sol-Gel Technologies 14
Sol-Gel Technologies Enters Into Licensing Agreement With US-Based Pharma Company For Dermatologic Drug 15
Sol-Gel Tech Raises USD86.3 Million in IPO of Shares 16
Mori Arkin Plans to Acquire Sol-Gel for USD10 Million 18
Sol-Gel Technologies Ltd, Key Competitors 19
Sol-Gel Technologies Ltd, Key Employees 20

List of Figures
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sol-Gel Technologies Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Sol-Gel Technologies Ltd (SLGL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dongfang Electric Corporation Ltd (1072):企業の財務・戦略的SWOT分析
    Dongfang Electric Corporation Ltd (1072) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Young & Co.’s Brewery plc (YNGA):企業の財務・戦略的SWOT分析
    Young & Co.'s Brewery plc (YNGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Ramco-Gershenson Properties Trust:企業のM&A・事業提携・投資動向
    Ramco-Gershenson Properties Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ramco-Gershenson Properties Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Gammon Construction Ltd:企業の戦略的SWOT分析
    Gammon Construction Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Dana Brevini Spa
    Dana Brevini Spa - Strategy, SWOT and Corporate Finance Report Summary Dana Brevini Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • SurModics Inc (SRDX)-医療機器分野:企業M&A・提携分析
    Summary SurModics Inc (SurModics) is a provider of device drug delivery coating and in vitro diagnostic technologies. The company offers wide range of advanced technologies that includes medical device coating technologies and surface modification coating technologies. Its technologies are employed …
  • Zebra Technologies Corp (ZBRA):企業の財務・戦略的SWOT分析
    Zebra Technologies Corp (ZBRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Edward Don & Company:企業の戦略・SWOT・財務情報
    Edward Don & Company - Strategy, SWOT and Corporate Finance Report Summary Edward Don & Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Medivir AB:企業のM&A・事業提携・投資動向
    Medivir AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Medivir AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Toyo Tanso Co Ltd (5310):企業の財務・戦略的SWOT分析
    Toyo Tanso Co Ltd (5310) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • CK Infrastructure Holdings Ltd (1038):電力:M&Aディール及び事業提携情報
    Summary CK Infrastructure Holdings Limited (CKI), a subsidiary of CK Hutchison Holdings Limited, is an infrastructure investment company. It holds diversified investment interests across various sectors including energy, rail transportation, water, waste management, and other infrastructure related …
  • Ebiquity plc (EBQ):企業の財務・戦略的SWOT分析
    Summary Ebiquity plc (Ebiquity) is a marketing and media consultancy service provider. The company offers services such as marketing performance optimization services, media value measurement and market intelligence. Its business areas comprise data analytics and advanced analytics. Ebiquity’s data …
  • Genesis Energy Ltd (GNE):電力:M&Aディール及び事業提携情報
    Summary Genesis Energy Ltd (Genesis) is an energy company. It generates electricity and supplies that on retail and wholesale basis. The company also supplies gas and LPG, and related services to end-users; and sells and purchases electricity derivatives. Genesis produces power using coal, gas, hydr …
  • CorEnergy Infrastructure Trust Inc (CORR):石油・ガス:M&Aディール及び事業提携情報
    Summary CorEnergy Infrastructure Trust Inc (CorEnergy) is an energy infrastructure real estate investment trust. The company owns assets in the midstream and downstream US energy sectors that perform functions, such as pipelines, storage terminals, and transmission and distribution assets. Its portf …
  • Petroleos Mexicanos:企業の戦略的SWOT分析
    Petroleos Mexicanos - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Leprino Foods Co:企業の戦略的SWOT分析
    Leprino Foods Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Nuance Communications, Inc. (NUAN)-医療機器分野:企業M&A・提携分析
    Summary Nuance Communications, Inc. (Nuance) is a provider of speech and imaging solutions. It offers solutions such as automated speech recognition, dialog management, capabilities for natural language understanding, optical character recognition (OCR), domain knowledge and implementation capabilit …
  • Humana Inc (HUM):企業の財務・戦略的SWOT分析
    Humana Inc (HUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Societe BIC (BB):企業の財務・戦略的SWOT分析
    Societe BIC (BB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Neovasc Inc (NVC):企業の財務・戦略的SWOT分析
    Summary Neovasc Inc (Neovasc) is a medical device manufacturing company that manufactures, develops, and sells cardiovascular disease products. The company’s products include Neovasc reducer, Neovasc tiara, and Neovasc tissue products. Its Neovasc tiara is a novel transcatheter device that is design …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆